BiotechTube

BNT331

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacterial Vaginosis

Conditions

Bacterial Vaginosis

Trial Timeline

Jul 1, 2024 → Jul 31, 2025

NCT ID
NCT06469164

About BNT331

BNT331 is a phase 1 stage product being developed by BioNTech for Bacterial Vaginosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06469164. Target conditions include Bacterial Vaginosis.

What happened to similar drugs?

18 of 20 similar drugs in Bacterial Vaginosis were approved

Approved (18) Terminated (2) Active (2)
✅Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
✅Azithromycin + MoxifloxacinMerckApproved
✅AzaSite (azithromycin ophthalmic solution) + Vigamox (moxifloxacin hydrochloride ophthalmic solution)MerckApproved
✅AzaSite Eye Drops + Vigamox Eye DropsMerckApproved
✅Colposeptine + MetronidazoleMerckApproved
✅Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal RingMerckApproved
✅Tigecycline + ampicillin-sulbactamPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06469164Phase 1Completed

Competing Products

20 competing products in Bacterial Vaginosis

See all competitors
ProductCompanyStageHype Score
ASP3652 + PlaceboAstellas PharmaPhase 2
35
Cefiderocol + Standard of CareShionogiPhase 2
35
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
21
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
29
Cefiderocol + Standard of CareShionogiPhase 2
35
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
29
Xeruborbactam + Cefiderocol + Xeruborbactam/Cefiderocol + Dextrose 5% in waterShionogiPhase 1
29
CefiderocolShionogiPre-clinical
26
Cefiderocol + Standard of CareShionogiPhase 2
35
Cefiderocol/XeruborbactamShionogiPhase 1
36
DoripenemJohnson & JohnsonPhase 3
40
levofloxacinJohnson & JohnsonPhase 3
40
Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
50
doripenemJohnson & JohnsonPhase 3
40
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
42
HRS-8427Jiangsu Hengrui MedicinePhase 1
29
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4AbbViePhase 2
42
DalbavancinAbbViePhase 1
21
V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™MerckPhase 3
40
AzaSite + TobramycinMerckPhase 3
40